default author photo

Terry Nolan

University of Melbourne - Peter Doherty Institute for Infection and Immunity

SCHOLARLY PAPERS

2

DOWNLOADS

128

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4 th Dose Booster

Number of pages: 43 Posted: 29 Jun 2023
University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne - Departments of Medicine and Infectious Diseases at the Doherty Institute, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne, Flinders University, University of Melbourne, University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Centre for Epidemiology and Biostatistics, University of Melbourne, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, SingHealth Duke-NUS Global Health Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), Flinders University, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, Monash University - Monash Institute of Pharmaceutical Sciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Monash University - Monash Institute of Pharmaceutical Sciences and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 128 (569,079)

Abstract:

Loading...

SARS-CoV-2, vaccine, receptor binding domain, recombinant protein, mRNA, beta variant, phase I trial.

2.

Capturing the Value of Vaccination within Health Technology Assessment and Health Economics

16TH VACCINE CONGRESS:P1.35
Posted: 19 Oct 2022
Creativ-Ceutical, Creativ-Ceutical, Creativ-Ceutical, University of Melbourne - Peter Doherty Institute for Infection and Immunity, Creativ-Ceutical, Creativ-Ceutical, University of Exeter - Faculty of Health and Life Sciences, Creativ-Ceutical, University of Duisburg-Essen - Institute for Health Care Management, Creativ-Ceutical, University of Groningen - Unit of Global Health, Creativ-Ceutical, Creativ-Ceutical, GlaxoSmithKline and Creativ-Ceutical

Abstract:

Loading...